{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:21:23Z","timestamp":1776813683778,"version":"3.51.2"},"reference-count":79,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.pnpbp.2010.07.029","type":"journal-article","created":{"date-parts":[[2010,8,6]],"date-time":"2010-08-06T09:00:33Z","timestamp":1281085233000},"page":"1333-1341","source":"Crossref","is-referenced-by-count":25,"title":["Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia"],"prefix":"10.1016","volume":"34","author":[{"given":"Dimitrios","family":"Kontis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirini","family":"Theochari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spyridon","family":"Kleisas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stamatina","family":"Kalogerakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angeliki","family":"Andreopoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Psaras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yannis","family":"Makris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charalambos","family":"Karouzos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleftheria","family":"Tsaltas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2010.07.029_bb0010","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0920-9964(92)90003-N","article-title":"Reliability and validity of a depression rating scale for schizophrenics","volume":"6","author":"Addington","year":"1992","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0015","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.4088\/JCP.v67n1211","article-title":"A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition","volume":"67","author":"Akdede","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0020","series-title":"Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"1994"},{"issue":"6","key":"10.1016\/j.pnpbp.2010.07.029_bb0025","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/S0010-9452(08)70294-6","article-title":"Spatial working memory and planning ability: contrasts between schizophrenia and bipolar I disorder","volume":"41","author":"Badcock","year":"2005","journal-title":"Cortex"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0030","series-title":"Cognition in Schizophrenia, Impairments, Importance and Treatment Strategies","first-page":"241","article-title":"Cognitive effects of typical antipsychotic treatment: Another look","author":"Blyler","year":"2000"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0035","first-page":"3","article-title":"Teoria statistica delle classi e calcolo delle probabilita","volume":"8","author":"Bonferroni","year":"1936","journal-title":"Pubbl Istit Sup Sci Econ Commerc Firenze"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0040","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/schbul\/sbi020","article-title":"A summary of the FDA-NIMH-MATRICS workshop on clinical trial designs for neurocognitive drugs for schizophrenia","volume":"31","author":"Buchanan","year":"2005","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0447.2005.00589.x","article-title":"Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy","volume":"113","author":"Carnahan","year":"2006","journal-title":"Acta Psychiat Scand"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0050","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1093\/schbul\/16.3.477","article-title":"Neuroleptics: Effects on neuropsychological function in chronic schizophrenic patients","volume":"16","author":"Cassens","year":"1990","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0055","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1176\/appi.ajp.161.4.700","article-title":"Baldessarini RJ. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits","volume":"161","author":"Centorrino","year":"2004","journal-title":"Am J Psychiatry"},{"issue":"8","key":"10.1016\/j.pnpbp.2010.07.029_bb0060","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1176\/appi.ps.57.8.1094","article-title":"Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial","volume":"57","author":"Chakos","year":"2006","journal-title":"Psychiatr Serv"},{"issue":"1-3","key":"10.1016\/j.pnpbp.2010.07.029_bb0065","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.schres.2006.07.011","article-title":"A model of anticholinergic activity of atypical antipsychotic medications","volume":"88","author":"Chew","year":"2006","journal-title":"Schizophr Res"},{"issue":"7","key":"10.1016\/j.pnpbp.2010.07.029_bb0070","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1532-5415.2008.01737.x","article-title":"Anticholinergic activity of 107 medications commonly used by older adults","volume":"56","author":"Chew","year":"2008","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0075","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.schres.2005.02.013","article-title":"Manual for the Extrapyramidal Rating Scale (ESRS)","volume":"76","author":"Chouinard","year":"2005","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2010.07.029_bb0080","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2006.08.017","article-title":"Does antipsychotic polypharmacy increase the risk for metabolic syndrome?","volume":"89","author":"Correll","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0085","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1176\/appi.ajp.2008.08060806","article-title":"Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST)","volume":"166","author":"Davidson","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.jcp.0000117422.05703.ae","article-title":"Dose response and dose equivalence of antipsychotics","volume":"24","author":"Davis","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0095","doi-asserted-by":"crossref","first-page":"998","DOI":"10.4088\/JCP.v63n1107","article-title":"Excessive antipsychotic dosing in 2 U.S. state hospitals","volume":"63","author":"Diaz","year":"2002","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2010.07.029_bb0100","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/schbul\/sbn097","article-title":"Systemic hypotheses for generalized cognitive deficits in schizophrenia: a new take on an old problem","volume":"35","author":"Dickinson","year":"2009","journal-title":"Schizophr Bull"},{"issue":"7","key":"10.1016\/j.pnpbp.2010.07.029_bb0105","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1177\/0269881108100777","article-title":"Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder","volume":"24","author":"Elie","year":"2010","journal-title":"J Psychopharmacol"},{"issue":"1","key":"10.1016\/j.pnpbp.2010.07.029_bb0110","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-5-26","article-title":"Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics","volume":"5","author":"Faries","year":"2005","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2010.07.029_bb0115","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3758\/BF03193146","article-title":"G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences","volume":"39","author":"Faul","year":"2007","journal-title":"Behav Res Methods"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0120","first-page":"445","article-title":"Effects of antipsychotic drugs on neuropsychological measures","volume":"Vol. 120","author":"Faustman","year":"1996"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0125","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1034\/j.1600-0447.2002.01331.x","article-title":"Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations","volume":"106","author":"Freudenreich","year":"2002","journal-title":"Acta Psychiatr Scand"},{"issue":"10","key":"10.1016\/j.pnpbp.2010.07.029_bb0130","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4088\/JCP.v65n1013","article-title":"Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid eligible schizophrenia patients, 1998\u20132000","volume":"65","author":"Ganguly","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0135","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.schres.2004.09.008","article-title":"Cognitive deficits as treatment targets in schizophrenia","volume":"72","author":"Gold","year":"2004","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0140","series-title":"Neuropsychopharmacology: The Fifth Generation of Progress","first-page":"657","article-title":"Neurocognitive functioning in patients with schizophrenia: An overview","author":"Goldberg","year":"2002"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1192\/bjp.162.1.43","article-title":"The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia","volume":"162","author":"Goldberg","year":"1993","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0150","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archpsyc.64.10.1115","article-title":"Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: Is it a practice effect?","volume":"64","author":"Goldberg","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0155","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia?","volume":"153","author":"Green","year":"1996","journal-title":"Am J Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2010.07.029_bb0160","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1176\/appi.ajp.164.7.992","article-title":"Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions","volume":"164","author":"Green","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0165","series-title":"ECDEU Assessment Manual for Psychopharmacology. Rockville","year":"1976"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0170","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/0006-3223(93)90043-D","article-title":"Improvement in cognitive functions and psychiatric symptoms in treatment refractory schizophrenic patients receiving clozapine","volume":"34","author":"Hagger","year":"1993","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2010.07.029_bb0175","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/0024-3205(88)90519-X","article-title":"Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites","volume":"43","author":"Hals","year":"1988","journal-title":"Life Sci"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0180","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1176\/appi.ajp.158.2.176","article-title":"Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment","volume":"158","author":"Harvey","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0185","series-title":"Handbook of Clinical Neuropsychology","first-page":"481","article-title":"Effects of psychiatric disorders and their somatic treatments on neuropsychological test results","author":"Heaton","year":"1981"},{"issue":"5","key":"10.1016\/j.pnpbp.2010.07.029_bb0190","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa053222","article-title":"Clozapine alone versus clozapine and risperidone with refractory schizophrenia","volume":"354","author":"Honer","year":"2006","journal-title":"N Engl J Med"},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2010.07.029_bb0195","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.schres.2006.05.004","article-title":"Antipsychotic medication and cognitive function in schizophrenia","volume":"86","author":"Hori","year":"2006","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0200","unstructured":"Invega (paliperidone) [package insert]. Titusville, NJ:Janssen LP; April 2007."},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0205","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1192\/bjp.187.3.243","article-title":"Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription","volume":"187","author":"Ito","year":"2005","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0210","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pds.783","article-title":"Antipsychotic medication coprescribing in a large state hospital system","volume":"12","author":"Jaffe","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0215","first-page":"55","article-title":"Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy","volume":"8","author":"Kane","year":"1998"},{"issue":"6","key":"10.1016\/j.pnpbp.2010.07.029_bb0220","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.pnpbp.2006.03.013","article-title":"High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction","volume":"30","author":"Kawai","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2010.07.029_bb0225","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"issue":"6","key":"10.1016\/j.pnpbp.2010.07.029_bb0230","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch Gen Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2010.07.029_bb0235","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1176\/appi.ajp.2010.09070937","article-title":"Processing Speed Deficits in Schizophrenia: Reexamining the Evidence","volume":"167","author":"Knowles","year":"2010","journal-title":"Am J Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2010.07.029_bb0240","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2006.02.023","article-title":"Long term combination antipsychotic treatment in VA patients with schizophrenia","volume":"84","author":"Kreyenbuhl","year":"2006","journal-title":"Schizophr Res"},{"issue":"4","key":"10.1016\/j.pnpbp.2010.07.029_bb0245","first-page":"271","article-title":"Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial","volume":"31","author":"Lal","year":"2006","journal-title":"J Psychiatry Neurosci"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/oxfordjournals.schbul.a033302","article-title":"Translating research into practice: the Schizophrenia Patients Outcomes ResearchTeam (PORT) treatment recommendations","volume":"24","author":"Lehman","year":"1998","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0255","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1192\/pb.26.11.411","article-title":"The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients","volume":"26","author":"Lelliott","year":"2002","journal-title":"Psychiatric Bull"},{"issue":"2","key":"10.1016\/j.pnpbp.2010.07.029_bb0260","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.eurpsy.2006.11.004","article-title":"Computerized assessment of cognition in schizophrenia: promises and pitfalls of CANTAB","volume":"22","author":"Levaux","year":"2007","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0265","series-title":"Virginia A. Sadock (Author) Kaplan & Sadock's Comprehensive Textbook of Psychiatry","first-page":"2360","article-title":"Dopamine Receptor Antagonists (Typical Antipsychotics)","author":"Marder","year":"2000"},{"issue":"8","key":"10.1016\/j.pnpbp.2010.07.029_bb0270","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/archpsyc.1991.01810320088015","article-title":"A polydiagnostic application of operational criteria in studies of psychotic illness. Development and reliability of the OPCRIT system","volume":"48","author":"McGuffin","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0275","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0887-6177(88)90018-2","article-title":"The effects of neuroleptics on neuropsychological test results of schizophrenics","volume":"3","author":"Medalia","year":"1988","journal-title":"Arch Clin Neuropsychol"},{"issue":"1","key":"10.1016\/j.pnpbp.2010.07.029_bb0395","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1176\/appi.ajp.161.1.116","article-title":"Association of anticholinergic load with impairment of complex attention and memory in schizophrenia","volume":"161","author":"Minzenberg","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0280","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2004.01.027","article-title":"A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book","volume":"55","author":"Mishara","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0285","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0091-3057(96)00425-X","article-title":"Cognitive function in schizophrenia\u2014do neuroleptics make a difference?","volume":"56","author":"Mortimer","year":"1997","journal-title":"Pharmacol Biochem Behav"},{"issue":"Pt 10","key":"10.1016\/j.pnpbp.2010.07.029_bb0290","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1093\/brain\/120.10.1823","article-title":"Frontal-striatal cognitive deficits in patients with chronic schizophrenia","volume":"120","author":"Pantelis","year":"1997","journal-title":"Brain"},{"issue":"4","key":"10.1016\/j.pnpbp.2010.07.029_bb0295","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s002130050300","article-title":"Effects of haloperidol and amisulpride on motor and cognitive skill learning in healthy volunteers","volume":"131","author":"Peretti","year":"1997","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0300","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1176\/ajp.143.2.230","article-title":"Memory deficits and anticholinergic levels in chronic schizophrenia","volume":"143","author":"Perlick","year":"1986","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2010.07.029_bb0305","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1177\/070674370104600404","article-title":"A antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution","volume":"46","author":"Procyshyn","year":"2001","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0310","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/s-2004-827174","article-title":"High dose antipsychotic use in schizophrenia: findings of the REAP (Research on East Asia Psychotropic Prescriptions) study","volume":"37","author":"Sim","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2010.07.029_bb0315","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1365-2125.2008.03304.x","article-title":"High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies","volume":"67","author":"Sim","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0320","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1037\/0021-843X.98.4.367","article-title":"Relation of neuroleptic and anticholinergic medication to cognitive functions of schizophrenia","volume":"98","author":"Spohn","year":"1989","journal-title":"J Abnorm Psychol"},{"issue":"3","key":"10.1016\/j.pnpbp.2010.07.029_bb0325","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/0929867043456070","article-title":"A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation","volume":"11","author":"Stahl","year":"2004","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0330","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0006-8993(88)91227-9","article-title":"Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations","volume":"472","author":"Sunderland","year":"1988","journal-title":"Brain Res"},{"issue":"1","key":"10.1016\/j.pnpbp.2010.07.029_bb0335","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1176\/appi.ps.54.1.55","article-title":"Combination antipsychotic therapy in clinical practice","volume":"54","author":"Tapp","year":"2003","journal-title":"Psychiatr Serv"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0340","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","article-title":"11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)","volume":"374","author":"Tiihonen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0345","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1176\/ajp.139.11.1460","article-title":"Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients","volume":"139","author":"Tune","year":"1982","journal-title":"Am J Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2010.07.029_bb0350","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.psychres.2004.09.007","article-title":"Stability of set-shifting and planning abilities in patients with schizophrenia","volume":"129","author":"Tyson","year":"2004","journal-title":"Psychiatry Res"},{"issue":"6","key":"10.1016\/j.pnpbp.2010.07.029_bb0355","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1080\/13803390490918534","article-title":"A longitudinal analysis of memory in patients with schizophrenia","volume":"27","author":"Tyson","year":"2005","journal-title":"Clin Exp Neuropsychol"},{"issue":"9","key":"10.1016\/j.pnpbp.2010.07.029_bb0400","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","article-title":"The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia","volume":"166","author":"Vinogradov","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0360","series-title":"Wechsler Adult Intelligence Scale-III (WAIS-III)","author":"Wechsler","year":"1997"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2009.05.018","article-title":"Influence of antipsychotics on mortality in schizophrenia: Systematic review","volume":"113","author":"Weinmann","year":"2009","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0370","series-title":"WHO Collaborating Centre for Drug Statistics Methodology: ATC classification index with DDDs 2008","author":"WHO","year":"2008"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0375","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics","volume":"64","author":"Woods","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0380","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1017\/S146114570500516X","article-title":"A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia","volume":"8","author":"Woodward","year":"2005","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0385","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.schres.2006.08.021","article-title":"A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects","volume":"89","author":"Woodward","year":"2007","journal-title":"Schizophr Res"},{"key":"10.1016\/j.pnpbp.2010.07.029_bb0390","doi-asserted-by":"crossref","unstructured":"Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry. 2010; 23(2):103\u201311.","DOI":"10.1097\/YCO.0b013e3283366427"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610002952?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584610002952?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,9]],"date-time":"2018-12-09T00:51:43Z","timestamp":1544316703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584610002952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":79,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0278584610002952"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2010.07.029","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}